Introduction
Proteasome inhibitors have recently demonstrated promise as potential novel anticancer therapies, since they induce apoptosis of tumor cells in vitro despite the accumulation of p21
Cip1 and p27 Kip1 (Hideshima et al., 2001c; Sun et al., 2001 ) and irrespective of p53 wild-type or mutant status (Lopes et al., 1997; Herrmann et al., 1998) . Specifically, PS-341 (pyrazylcarbonyl-Phe-Leuboronate, bortezomib) represents a class of peptide boronate proteasome inhibitors which inhibit 26S proteasome activity (Kisselv and Goldberg, 2001) . We have previously demonstrated that PS-341 induces heat shock proteins (Hsps), activates JNK, and induces apoptosis in MM cells mediated by activation of caspase-8, -9, and -3, without alteration of Bax or Bcl-2 protein expression (Hideshima et al., 2001c; Mitsiades et al., 2002) . It also induces cleavage of DNA protein kinase catalytic subunit (DNA-PKcs) and ATM (Hideshima et al., 2003e) , overcomes conventional drug resistance conferred by IL-6 or adherence to bone marrow stromal cells (BMSCs) (Hideshima et al., 2001c) , and further abrogates IL-6-triggered signaling cascades by caspase-dependent downregulation of gp130 (CD130) . We have extended these promising in vitro findings to in vivo preclinical studies and clinical trials. PS-341 inhibits human MM cell growth and associated angiogenesis, as well as prolonging survival, in a murine SCID mouse model (LeBlanc et al., 2002) . Most importantly, PS-341 has achieved responses, even complete responses, in a phase II clinical trial treating patients with relapsed MM refractory to conventional therapies . This drug therefore represents a new treatment paradigm targeting not only the tumor cell, but also the MM cell-host interaction and the BM milieu, to overcome drug resistance and improve patient outcome.
p38 mitogen-activated protein kinase (MAPK) is a member of the MAPK family which is activated by cytokines and growth factors, but its role in pathogenesis of MM is unknown. We have previously demonstrated that the specific p38 MAPK inhibitor VX-745 (Vertex Pharmaceuticals Inc, Cambridge, MA, USA) inhibits paracrine MM cell growth, associated with downregulation of IL-6 and VEGF secretion in bone marrow stromal cells (BMSCs). Furthermore, p38 MAPK inhibition blocks TNFa-induced IL-6 secretion in BMSCs , thereby further inhibiting MM cell growth and survival . Previous reports have also demonstrated that p38 MAPK regulates Hsp27 via either MAP kinase-activated protein kinase 2 (MAPKAPK2) and/or p38 MAPK-regulated/activated protein kinase (PRAK) (Landry and Huot, 1995; Beyaert et al., 1996; Guay et al., 1997; Huot et al., 1997; New et al., 1998) . Our recent studies have shown that Hsp27 overexpression is associated with resistance to dexamethasone (Dex); conversely, anti-sense Hsp27 restores sensitivity to Dex via triggering release of second mitochondria-derived activator of caspases (Smac), followed by activation of caspase-9 and -3 . We have also used gene microarray and Western blotting analyses to demonstrate high Hsp27 RNA levels and protein expression in PS-341-resistant tumor cells, and, importantly, that blockade of Hsp27 restores sensitivity to PS-341 . Whether p38 MAPK inhibition may enhance sensitivity to PS-341 by downregulating Hsp27 is not yet defined.
Although PS-341 achieved 35% responses in relapsed and refractory MM patients, the majority of the patients did not respond. In the present study, we therefore determined whether inhibition of p38 MAPK augments cytotoxicity against MM cells by downregulating PS-341-triggered upregulation of Hsp27, and may thereby improve patient outcome. In this study we used SCIO-469, which belongs to a new class of treatments that inhibit p38 MAPK and is already under evaluation in phase II clinical trials in rheumatoid arthritis patients. Both SCIO-469 and p38 MAPK siRNA significantly augmented PS-341-triggered MM cell line apoptosis, associated with downregulation of Hsp27. Most importantly, treatment with SCIO-469 enhanced PS-341 cytotoxicity even in PS-341-resistant patient MM cells, providing the framework for clinical trials combining these agents to improve patient outcome in MM.
Results

SCIO-469 inhibits IL-6 secretion in BMSCs
Since we have previously shown that p38 MAPK inhibitor VX-745 inhibits both IL-6 and VEGF secretion from MM patients' BMSCs , we first similarly examined whether SCIO-469 inhibits secretion of these cytokines from BMSCs. Growth of BMSCs from three MM patient BMSCs was not inhibited by , assessed by MTT assay (Figure 1a) . Importantly, SCIO-469 (0.16-500 nM) significantly inhibited IL-6 secretion from three MM patients BMSCs in a dose-dependent fashion (Figure 1b) , consistent with our previous studies . We next examined whether SCIO-469 inhibited IL-6 secretion in BMSCs triggered by TNFa, since TNFa activates p38 MAPK/NF-kB, thereby inducing IL-6 transcription and secretion in BMSCs (Hideshima et al., 2001a) . SCIO-469 significantly Inhibition of p38 MAPK enhances PS-341cytotoxicity T Hideshima et al (Po0.01) inhibits TNFa-triggered upregulation of IL-6 secretion in BMSCs (Figure 1c ).
SCIO-469 inhibits phosphorylation of p38 MAPK in MM cells
We first examined the inhibitory effect of SCIO-469 on phosphorylation of p38 MAPK triggered by TNFa in MM.1S cells. TNFa (5 ng/ml) induced phosphorylation of p38 MAPK, which peaked after 5 min (Figure 2a ). SCIO-469 (0-100 nM) pretreatment inhibited TNFainduced (5 ng/ml for 5 min) p38 MAPK phosphorylation in a dose-dependent fashion (Figure 2b) (Figure 2d ).
SCIO-469 inhibits PS-341-induced Hsp27 expression
We have demonstrated that PS-341 significantly upregulates Hsp27 expression in MM cells in a timedependent fashion Hideshima et al., 2003e) . Importantly, we have also shown that blocking Hsp27 in tumor cells using antisense strategy can overcome resistance to PS-341; conversely, overexpression of wild-type Hsp27 confers PS-341 resistance in tumor cell lines . Since p38 MAPK phosphorylates Hsp27 via either MAPKAPK2 and/or PRAK (Landry and Huot, 1995; Beyaert et al., 1996; Guay et al., 1997; Huot et al., 1997; New et al., 1998) , thereby enhancing Hsp27 oligomerization and activity, we hypothesized that inhibition of p38 MAPK activity by SCIO-469 could block PS-341-induced upregulation and/or phosphorylation of Hsp27 in MM cells, thereby augmenting its cytotoxicity (Figure 3a ). Since our gene microarray data indicated significant upregulation of Hsp27 gene expression after 3 h treatment with PS-341 (Figure 3b ), we next treated MM.1S cells with PS-341 to confirm whether PS-341 could induce phosphorylation of p38 MAPK. As expected, PS-341 triggered phosphorylation of p38 MAPK in a time-dependent fashion in MM.1S cells (Figure 3c ). We further confirmed the inhibitory effect of SCIO-469 on both phosphorylation of p38 MAPK and kinase activity on MAPKAPK2 in MM.1S cells after treatment with PS-341, using Western blotting and in vitro MAPK-KAPK2 kinase assay. Although PS-341 triggered both phosphorylation of p38 MAPK (Figure 3d ) and induced phosphorylation of Hsp27 via activation of MAP-KAPK2 (Figure 3e ), SCIO-469 inhibited phosphorylation of both p38 MAPK and Hsp27. Consistent with our previous studies , PS-341 significantly upregulated Hsp27 expression in MM.1S cells; importantly, pretreatment with SCIO-469 inhibited induction of Hsp27 by PS-341 (Figure 3f ). Protein expression of Hsp70 or p38 MAPK was not affected by SCIO-469 treatment. These results demonstrate that PS-341 activates p38 MAPK, followed by activation of MAPKAPK2, as well as upregulation and phosphorylation of Hsp27, which is inhibited by p38 MAPK inhibitor SCIO-469.
SCIO-469 augments cytotoxicity of PS-341, associated with caspase-8 and PARP cleavage, in MM.1S, U266, and RPMI8226 cells We next examined the mechanism whereby inhibiting p38 MAPK augments cytotoxicity of PS-341. Since we have previously reported that apoptotic stimuli, including PS-341 (Hideshima et al., 2003e) , 2ME-2 , and lysophosphatidic acid acyltransferaseb inhibitor , induce apoptosis via activation of JNK, we determined whether SCIO-469 augmented phosphorylation of JNK, as well as cleavage of caspase-8 and PARP, hallmarks of PS-341-triggered apoptosis in MM.1S cells (Hideshima et al., 2001c Mitsiades et al., 2002) . PS-341 (20 nM; 6 h) treatment slightly induced JNK phosphorylation in MM.1S cells; however, SCIO-469 significantly upregulated JNK phosphorylation. Importantly, SCIO-469 also enhanced cleavage of caspase-8 and PARP (Figure 4c , left panel). We further examined whether SCIO-469 could also enhance phosphorylation of JNK and cleavage of caspase-8 and PARP after 24 h treatment with low-dose (5 nM) PS-341. SCIO-469 enhanced PS-341-induced phosphorylation of JNK, as well as cleavage of caspase-8 and PARP ( Figure 4c , right panel), to levels greater than those observed after 20 nM PS-341 treatment for 6 h. These results suggest that enhancement of PS-341 cytotoxicity induced by SCIO-469 is associated with upregulation of JNK activity, followed by caspase-8/PARP cleavage.
We further examined whether SCIO-469 could similarly augment cytotoxicity of PS-341 in U266 and RPMI8226 cells. Consistent with the inhibitory effect of SCIO-469 on baseline phosphorylation of p38 MAPK in these cell lines (Figure 2a ), SCIO-469 (100 and 200 nM) also significantly enhanced PS-341-induced cytotoxicity in U266 (Figure 5a and b) and RPMI8226 ( Figure 5d and e) cells. Importantly, cleavage of both caspase-8 and PARP was enhanced by SCIO-469.
SCIO-469 inhibits upregulation of p21
Cip1 triggered by PS-341
We have previously shown that PS-341 transiently induces G2/M growth arrest in MM cells, associated with upregulation of p21
Cip1 and/or p27
Kip1
, followed by apoptosis (Hideshima et al., 2001c) . We therefore next . Moreover, SCIO-469 did not alter upregulation of p53, a proteasome substrate (Figure 6a ). To confirm the functional sequelae of these changes, we next performed cell cycle analysis in MM.1S cells after treatment with PS-341 and SCIO-469. PS-341 induced G2/M phase (black line); however, pretreatment with SCIO-469 (green line) inhibited this effect (Figure 6b ). SCIO-469 alone did not alter cell MM.1S cell cycle profile (data not shown). These results suggest that SCIO-469 prevents MM cells from remaining in G2/M phase, thereby promoting apoptosis.
p38 MAPK siRNA inhibits PS-341-induced Hsp27 and p21
Cip1 upregulation, and augments cytotoxicity of PS-341 , as well as phosphorylation of JNK. As observed after SCIO-469 treatment, p38 MAPK siRNA inhibited PS-341-induced upregulation of Hsp27 and p21
Cip1
, and augmented phosphorylation of JNK (Figure 7b ). These results confirm that specific inhibition of p38 MAPK blocks PS-341-triggered upregulation of Hsp27 and p21
.
To confirm the biologic significance of p38 MAPK inhibition in PS-341-treated MM cells, p38 MAPK siRNA was transfected into MM.1S cells. After 36 h incubation, transfectants were cultured for 24 h in the presence of PS-341 (2.5 nM). Importantly, 40% growth inhibition was noted in p38 MAPK siRNA MM.1S transfectants after treatment with 2.5 nM PS-341 (Figure 7c ). Therefore, inhibition of p38 MAPK augments PS-341-triggered cytotoxicity in MM cells. 
SCIO-469 inhibits phosphorylation of Hsp27 and enhances cytotoxicity of PS-341 in DHL-4 cells
SCIO-469 enhances PS-341 cytotoxicity even against PS-341-resistant patient MM cells
We have recently reported significant anti-MM activity of PS-341 in a phase II clinical trial treating patients with relapsed refractory myeloma . However, some patients have intrinsic or develop resistance to PS-341, and we next therefore examined whether SCIO-469 could enhance PS-341-induced cytotoxicity even against PS-341-resistant patient MM cells. 
Inhibition of p38 MAPK enhances PS-341cytotoxicity T Hideshima et al
Importantly, SCIO-469 further significantly (Po0.01) enhanced PS-341-induced cytotoxicity ( Figure 9 ). This result suggests that SCIO-469 can overcome clinical resistance to PS-341.
Discussion
We have previously demonstrated that PS-341 directly inhibits proliferation and induces apoptosis of human MM cell lines and freshly isolated patient MM cells (Hideshima et al., 2001c) . PS-341 induces apoptosis via activation of caspase-8, -9, and -3, followed by PARP cleavage, in both p53 wild-type and p53 mutant MM cells (Hideshima et al., 2001c Mitsiades et al., 2002) . It induces apoptosis even in drug-resistant cells, and adds to the anti-MM activity of Dex. Importantly, IL-6 does not protect against PS-341-induced apoptosis in MM cells (Hideshima et al., 2001c Inhibition of p38 MAPK enhances PS-341cytotoxicity T Hideshima et al cell lines, as well as in patient tumor cells .
Most excitingly, PS-341 demonstrated significant in vivo antitumor activity in SCID mouse models of human MM (LeBlanc et al., 2002) and in clinical trials. In patients with relapsed and refractory MM, PS-341 achieved 35% responses, including complete responses, and achieved clinical benefit . However, 65% of patients were nonresponders, and some patients developed PS-341 resistance. Although Pglycoprotein and CYP3A4 have been demonstrated to play an important role in drug resistance Christians et al., 2002; Schwarzenbach, 2002) , expression of these proteins in PS-341 resistant cells has not yet been delineated. To overcome resistance and improve patient outcome, several therapeutic strategies have been employed. First, we have shown that PS-341 induces cleavage of DNA-PKcs and ATM (Hideshima et al., 2003e) , thereby inhibiting DNA repair; conversely, PS-341 significantly enhances sensitivity or overcomes resistance to DNA damaging agents (i.e., doxorubicin and melphalan) (Mitsiades et al., 2003) . Based upon these preclinical results, clinical trials are underway using the combination of PS-341 with DNA-damaging agents Doxil and melphalan; these protocols have already achieved remarkable responses in patients whose disease is resistant to these agents Yang et al., 2003) .
In this study, we attempted to develop an alterative strategy to overcome PS-341 resistance, based upon inhibiting molecular mechanisms mediating drug Inhibition of p38 MAPK enhances PS-341cytotoxicity T Hideshima et al resistance. First, we have shown that PS-341 induces Hsps, including Hsp70 and Hsp90, in MM cells Hideshima et al., 2003e) . Since Hsps inhibit apoptotic signaling at several levels (Creagh et al., 2000; Jolly and Morimoto, 2000; Xanthoudakis and Nicholson, 2000) , upregulation of Hsps in PS-341-triggered MM cells may protect against apoptosis. We have also shown that Hsp27 is markedly upregulated after PS-341 treatment Hideshima et al., 2003e) ; conversely, our data demonstrate that inhibition of Hsp27 overcomes PS-341 resistance . Overexpression of Hsp27 also inhibits mitochondrial release of second mitochondriaderived activator of caspases (Smac), and thereby confers Dex resistance in MM cells . Second, p38 MAPK modulates IL-6 transcription and secretion (Vanden Berghe et al., 1998; Craig et al., 2000) , and we have shown that p38 MAPK inhibitor VX-745 inhibits paracrine MM cell growth, associated with downregulation of IL-6 secretion in BMSCs . Importantly, p38 MAPK also regulates Hsp27 activity via either MAP-KAPK2 and/or PRAK (Landry and Huot, 1995; Beyaert et al., 1996; Guay et al., 1997; Huot et al., 1997; New et al., 1998) , suggesting that inhibition of p38 MAPK may also sensitize MM cells to PS-341 by downregulating and/or inactivating Hsp27. We demonstrated that SCIO-469 significantly inhibited constitutive and TNFa-triggered IL-6 secretion from BMSCs, consistent with our previous study . Since transcription and protein expression of IL-6 is regulated by NF-kB activation (Chauhan et al., 1996) , these results suggest that SCIO-469 inhibits TNFa-induced NF-kB activation and related induction of IL-6 in BMSCs. These results further suggest that SCIO-469 may inhibit cytokine (TNFa, IL-6)-induced paracrine MM cell growth in the BM microenvironment . SCIO-469 also inhibited baseline phosphorylation of p38 MAPK in MM cell lines; Inhibition of p38 MAPK enhances PS-341cytotoxicity T Hideshima et al however, no alteration of cell growth was observed in those cell lines. These results suggest that inhibition of p38 MAPK alone does not inhibit growth-signaling cascades in MM cells. To determine whether p38 MAPK inhibition alters sensitivity to PS-341 treatment, we first studied whether PS-341 could activate p38 MAPK. Importantly, PS-341 phosphorylates p38 MAPK and activates MAPKAPK2, followed by upregulation and/or phosphorylation of Hsp27, in MM cells. These results confirmed that upregulation of Hsp27 by PS-341 is mediated via p38 MAPK/MAPKAPK2 cascade. Conversely, a novel p38 MAPK inhibitor SCIO-469 blocked these effects, resulting in significantly increased cytotoxicity of PS-341 against MM cells. Induction of Hsp70 was not affected by p38 MAPK inhibitor, suggesting that Hsp27 may selectively mediate this protective effect in MM.1S cells.
We further studied the molecular mechanisms whereby SCIO-469 enhances cytotoxicity of PS-341 against MM cells. Since we have previously demonstrated that PS-341 induces activation of JNK followed by caspase cleavage, and, conversely, that blockade of JNK activity inhibits PS-341-induced apoptosis Hideshima et al., 2003e) , we next examined the effect of SCIO-469 on JNK phosphorylation, as well as on caspase-8 and PARP cleavage, triggered by PS-341. In our study, PS-341-induced JNK phosphorylation was enhanced by SCIO-469. Furthermore, caspase-8 and PARP cleavage was also enhanced by SCIO-469. Importantly, these effects were observed after both 6 h (40 nM) and 24 h (5 nM) treatments with PS-341. These results confirm that enhanced cytotoxicity of PS-341 triggered by SCIO-469 is mediated via JNK signaling cascade.
We have also previously shown that PS-341 induces an increase in G2/M phase in MM cells, associated with upregulation of p21
Cip1 and p27 Kip1 expression, followed by apoptosis (Hideshima et al., 2001c) . Interestingly, our studies demonstrate that upregulation of p21 Cip1 triggered by PS-341 is strongly inhibited by SCIO-469. The biologic significance of downregulating p21
Cip1 was confirmed by flow cytometric analysis, which demonstrates that SCIO-469 inhibits induction of G2/M phase. Taken together, these results suggest that SCIO-469 augments cytotoxicity, at least in part, by inhibiting growth arrest and thereby facilitating apoptosis. To confirm the specific affect of SCIO-469 on p38 MAPK, we carried out similar experiments using p38 MAPK siRNA. As observed after treatment with SCIO-469, p38 MAPK siRNA augments cytotoxicity of PS-341, enhances phosphorylation of JNK; as well as inhibits upregulation of Hsp27 and p21
Cip1
. We further studied whether SCIO-469 could also augment cytotoxicity of PS-341 in DHL-4 cells, which overexpress Hsp27 and are resistant to PS-341 . Consistent with our previous studies, SCIO-469 enhanced cytotoxicity of PS-341 in DHL-4 cells, associated with inhibition of PS-341-triggered phosphorylation of Hsp27. Finally, we also examined the cytotoxicity of combined treatment with SCIO-469 and PS-341 in patient MM cells resistant to PS-341. SCIO-469 significantly augments cytotoxicity of PS-341 in these cells, and its effect on Hsp27 expression in patient cells is under investigation. Our results therefore provide the preclinical rationale for clinical trials for SCIO-469 in combination with PS-341 to either enhance the sensitivity or overcome resistance to PS-341, thereby improving patient outcome.
Materials and methods
Reagents
p38 MAPK-specific inhibitor SCIO-469 was synthesized by Medicinal Chemistry at Scios Inc. (Fremont, CA, USA), dissolved in DMSO and stored at À201C until use. SCIO-469 has an in vitro IC 50 of 9 nM for inhibition of p38a, about 10-fold selectivity for p38a over p38b, and at least 2000-fold selectivity for p38a over an in vitro panel of 20 other kinases, including other MAK kinases. No significant affinity was detected in a panel of 70 enzymes and receptors. SCIO-469 was diluted in DMSO (40 mM stock solution) and kept at À201C until use. PS-341 was provided from Millennium Pharmaceuticals (Cambridge, MA, USA), diluted in DMSO (1 mM stock solution) and kept at À201C until use. TNFa was purchased from R&D Systems (Minneapolis, MN, USA). p38 MAPK siRNA was purchased from Dharmacon Inc. (Lafayette, CO, USA).
MM-derived cell lines and patient MM cells
Dex-sensitive MM.1S and -resistant MM.1R human MM cell lines were kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL, USA). U266 and RPMI8226 human MM cells were obtained from American Type Culture Collection (Rockville, MD, USA). Doxorubicin-resistant RPMI-Dox40 cell line was kindly provided by Dr William Dalton (H Lee Moffitt Cancer Center, Tampa, FL, USA). DHL-4 cell line was kindly provided by Dr Margaret Shipp (Dana-Farber Cancer Institute, Boston, MA, USA). All cell lines were cultured in RPMI-1640 containing 10% fetal bovine serum (FBS, Sigma Chemical Co., St Louis, MO, USA), 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (GIBCO, Grand Island, NY, USA). Patient MM cells were purified from patient BM aspirates by negative selection, as previously described .
BMSC cultures and ELISA
BM specimens were obtained from patients with MM. Mononuclear cells (MNCs) separated by Ficoll-Hypaque density sedimentation were used to establish long-term BM cultures, as previously described (Uchiyama et al., 1993) . When an adherent cell monolayer had developed, cells were harvested in Hank's buffered saline solution containing 0.25% trypsin and 0.02% EDTA, washed and collected by centrifugation. IL-6 levels in culture supernatants from BMSCs cultured for 24 h, in the presence or absence of SCIO-469, were quantitated by ELISA (DuoSet, R&D Systems) as previously described (Hideshima et al., 2001c) .
Growth inhibition assay
The inhibitory effect of SCIO-469 inhibitor on MM cell line growth was assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT, Chemicon International Inc., Temecula, CA, USA) dye absorbance, as previously described (Hideshima et al., 2000) .
Quantification of apoptosis (DNA fragmentation assay)
Cell Death Detection ELISA plus (Roche Applied Sciences, Indianapolis, IN, USA) was utilized to quantitate DNA fragmentation, as per manufacturer's instructions, as previously described (Chauhan et al., 2004) .
Oligonucleotide array analysis MM.1S cells were incubated with 20 nM PS-341 for 0.5, 1, 3, and 6 h in the presence of 5% FBS. Total RNA was extracted, subjected to expression profiling, and analysed using Affymetrix U133A arrays (Santa Clara, CA, USA), as previously described .
MAPKAP kinase2 kinase assay
MAPKAPK2 kinase assay was performed using MAPKAPK2 kinase assay kit (Upstate, Lake Placid, NY, USA). Briefly, MM.1S cells were pre-incubated with SCIO469 for 30 min, and then treated with PS-341 for 1 h. Whole-cell lysates (1 mg) were subjected to MAPKAPK2 immunoprecipitation kinase assay, according to the manufacturer's protocol.
Cell cycle analysis
MM.1S cells were treated with either 200 nM SCIO-469 or DMSO control prior to culture with 40 nM PS-341 for 12 h. Cell cycle analysis was performed, as in prior studies .
Immunoblotting
MM.1S cells were treated with SCIO-469 for 12 h prior to culture with 40 nM PS-341; cells were harvested, washed, and lysed, as in prior studies (Hideshima et al., 2000 (Hideshima et al., , 2001c . Cell lysates were subjected to SDS-PAGE, transferred to PVDF membrane (Bio-Rad Laboratories, Hercules, CA, USA), and immunoblotted with anti-phospho-p38 MAPK, phospho-JNK, p38 MAPK, phospho-Hsp27, Hsp27, p53, and poly ADP-ribose polymerase (PARP) Abs (Cell Signaling, Beverly, MA, USA), as well as with anti-JNK1, hsp70, p21 Cip1 , p27 Kip1 , and actin Abs (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Transient transfection of siRNA
MM.1S cells were transiently transfected with p38 MAPK siRNA using 'Cell Line Nucleofectot Kit V,' according to the manufacturer's (Amaxa Biosystems, Ko¨ln, Germany) instructions, as in prior studies Hideshima et al., 2003c) . Following transfection, MM.1S cells were subjected to Western blotting and MTT assay, in the presence or absence of PS-341.
Statistical analysis
The statistical significance of differences observed in drugtreated versus control cultures was determined using the Wilcoxon signed-ranks test. The minimal level of significance was Po0.05.
